BB Biotech AG reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was CHF 208.4 million compared to CHF 395.22 million a year ago. Basic loss per share from continuing operations was CHF 3.76 compared to CHF 7.13 a year ago. Diluted loss per share from continuing operations was CHF 3.76 compared to CHF 7.13 a year ago. For the nine months, revenue was CHF 187.17 million compared to CHF 61.97 million a year ago. Net income was CHF 141.1 million compared to CHF 26.49 million a year ago. Basic earnings per share from continuing operations was CHF 2.55 compared to CHF 0.48 a year ago. Diluted earnings per share from continuing operations was CHF 2.55 compared to CHF 0.48 a year ago.